Researchers at the University of Alabama are investigating whether a reduced sense of smell, or hyposmia, could be used as a biomarker to help detect Parkinson's disease.
Having failed so far to get its extended-release Parkinson's drug Rytary to market, Impax Laboratories ($IPXL) is turning to asking three big-name specialists what it should do.
Impax Laboratories is bringing in the big guns to help it accomplish what it has been unable to do on its own.
A team of researchers at Tel Aviv University has developed a biodegradable implant that delivers a gel capable of restoring healthy nerve function to treat diseases such as Parkinson's.
A massive, international study to find and evaluate potential Parkinson's disease biomarkers has finished enrolling a first group of 600 Parkinson's patients and controls.
Researchers at Northeastern University have developed a treatment for Parkinson's disease meant to revive dying neurons in the brain via delivery through the nose.
Civitas Therapeutics heralded a successful Phase II trial result for its inhaled Parkinson's drug CVT-301, the novel delivery of which promises to make the disease more manageable for patients on an everyday basis, the company says.
A deep brain stimulation implant used in a small pilot study helped some patients with severe anorexia gain weight and boosted their mood.
NIH is looping Emory's Rollins School of Public Health into its Parkinson's Disease Biomarker Program, pledging $900,000 to a research team aiming to discover new ways of identifying the ailment.
The FDA has thrown up a roadblock for Impax Laboratories' ($IPXL) extended-release version of a carbidopa-levodopa combo for Parkinson's disease now dubbed Rytary.